Miebo®
Perfluorohexyloctane 100% · ophthalmic solution
Dry Eye/OSD
Approved uses
Dry eye disease
1 drop QID in the affected eye(s)
OFF-LABELNot in the FDA label for this product
Lid wiper epitheliopathy
1 drop QID for 2 months (trial regimen)
RCT · n=52 · unmasked
Randomized, no-treatment-controlled study in 52 adults with symptomatic dry eye and a Korb lid wiper epitheliopathy score of 1.0 or greater: Korb and photographic LWE grades were significantly better than no treatment from week 2 onward, as were SPEED and symptom scores at 2 months, but the 0.5-unit or greater photographic improvement at 2 months reached significance in right eyes only (P=0.04). The authors state masked comparative trials are still needed.
Contraindications
History of hypersensitivity reaction to perfluorohexyloctane.
100% perfluorohexyloctane ophthalmic solution, 3 mL fill in a multiple-dose 5 mL bottle
Semifluorinated alkane (6 perfluorinated and 8 hydrogenated carbon atoms) that forms a monolayer at the air-liquid interface of the tear film, which can be expected to reduce evaporation. The exact mechanism of action in dry eye disease is not known.
Warnings & Precautions
Use with contact lenses: Do not administer while wearing contact lenses. Remove them before instillation and for at least 30 minutes after.
Common Side Effects
Blurred vision was the most common ocular adverse reaction; blurred vision and conjunctival redness were reported in 1% to 3% of individuals in two randomized controlled trials (614 patients treated). In four premarketing studies (three open-label, n=127; one randomized, n=24), the most common adverse reaction was hypersensitivity.
Pregnancy: No adequate and well controlled studies in pregnant women. Oral dosing in rats produced no embryofetal toxicity or teratogenicity up to 162 times the recommended human ophthalmic dose; rabbits showed maternal toxicity, miscarriages, and reduced fetal weights at all doses tested (lowest 41 times), without fetal malformations.
Lactation: No data on presence in human milk, effects on the breastfed infant, or milk production. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for this drug.
Safety and effectiveness below 18 years not established.